Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement

Jul

22

Today In Oncology

AI-Derived Bone Marrow Architecture Score Improves Disease Assessment in Myelodysplastic Neoplasms

Multiple Myeloma Studies Highlight Advances Across the Field

Early Research Examines Daraxonrasib in NRAS-Mutant Melanoma

Can Consolidative Thoracic Radiotherapy Improve Outcomes During Immunotherapy Maintenance in Extensive-Stage SCLC?

Treatment Delays May Increase Metastasis Risk in Nonmetastatic Colorectal Cancer

Advertisement

© 2026 HSP News Service, L.L.C.